|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Post-Menopausal Osteoporosis | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Osteoporosis | |||||
| Osteoporosis, Postmenopausal | |||||
| 3 | More general conditions related to this trial | ||||
| Bone Diseases | |||||
| Bone Diseases, Metabolic | |||||
| Musculoskeletal Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| ibandronate [Bonviva/Boniva] | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Ibandronic acid | |||||
| 6 | More general drug interventions related to this trial | ||||
| Bone Density Conservation Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| 7 | Sponsors listed in this trial | ||||
| Hoffmann-La Roche | |||||